Scarica l'app Stockscreener
132.90
1.21%
1.59
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Reversal Traders Monitor Neurocrine Biosciences Inc. for EntryJuly 2025 Institutional & Weekly Sector Rotation Insights - metal.it
Trendlines Converge — Decision Point for Neurocrine Biosciences Inc.July 2025 Recap & Stock Market Timing Techniques - beatles.ru
Earnings visualization tools for Neurocrine Biosciences Inc.2025 Price Targets & Precise Trade Entry Recommendations - Newser
Published on: 2025-08-15 16:55:58 - Newser
PNC Financial Services Group Inc. Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Neurocrine at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
US Bancorp DE Has $412,000 Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Stronger-Than-Expected Q2 Results Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - MSN
Neurocrine Biosciences Director Gorman Buys, Sells 106,322 Shares on 8/7/2025 - AInvest
Neurological Disorder Drugs Market Set to Witness Significant - openPR.com
Will Neurocrine Biosciences Inc. bounce back from current supportWatchlist Summary for Active Day Traders - Newser
Top chart patterns to watch in Neurocrine Biosciences Inc.5-Year Price Trend Summary and Analysis - Newser
What’s the recovery path for long term holders of Neurocrine Biosciences Inc.Breakout Screener With Alert Based Timing - Newser
What’s next for Neurocrine Biosciences Inc. stock priceFree Daily Growth Stock Pick Reports - Newser
Understanding Neurocrine Biosciences Inc.’s price movementAsset Growth Pattern and Return Summary - Newser
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 - GlobeNewswire Inc.
Neurocrine Biosciences shares rise 3.11% after-hours following Nxera Pharma's obesity pipeline progress. - AInvest
This Neurocrine Biosciences Insider Reduced Their Stake By 28% - 富途牛牛
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Neurocrine Biosciences shares fall 1.10% intraday as Nxera Pharma launches obesity drug pipeline. - AInvest
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Neurocrine CEO and IR Chief to Share Latest Growth Strategy at Major Biotech Conference - Stock Titan
Tardive Dyskinesia Drugs Market Exclusive Report with Detailed - openPR.com
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded at Wall Street Zen - Defense World
Guggenheim Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $175.00 - MarketBeat
CRENESSITY's Breakout Launch Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
William Blair Analysts Increase Earnings Estimates for NBIX - Defense World
What drives Neurocrine Biosciences Inc. stock priceUnlock powerful trading alerts for success - Jammu Links News
Is Neurocrine Biosciences Inc. a growth stock or a value stockTremendous wealth creation - Jammu Links News
Neurocrine Biosciences Inc. Stock Analysis and ForecastRapid portfolio appreciation - Jammu Links News
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $144.00 at Royal Bank Of Canada - MarketBeat
How does Neurocrine Biosciences Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
How many analysts rate Neurocrine Biosciences Inc. as a “Buy”Dynamic growth stocks - Jammu Links News
What is the risk reward ratio of investing in Neurocrine Biosciences Inc. stockAchieve consistent profits with expert advice - Jammu Links News
What makes Neurocrine Biosciences Inc. stock price move sharplyStay ahead with daily market updates - Jammu Links News
What is the dividend policy of Neurocrine Biosciences Inc. stockAchieve rapid financial growth with expert picks - Jammu Links News
Contradictions in Focus: Analyzing INGREZZA and Crinecerfont's Market Dynamics and Pricing Strategies - AInvest
How volatile is Neurocrine Biosciences Inc. stock compared to the marketExplosive earnings growth - Jammu Links News
Is Neurocrine Biosciences Inc. stock overvalued or undervaluedGet daily updates on promising stocks - Jammu Links News
What institutional investors are buying Neurocrine Biosciences Inc. stockUnlock real-time stock alerts for quick profits - Jammu Links News
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
NBIX FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript - Insider Monkey
Research Alert: CFRA Retains Hold Opinion On Shares Of Neurocrine Biosciences, Inc. - 富途牛牛
Neurocrine's Promising Outlook: Strong Crenessity Sales and Strategic Ingrezza Adjustments Drive Buy Rating. - AInvest
Guggenheim Raises Price Target for Neurocrine Biosciences, Maintains "Buy" Rating - AInvest
Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors - TipRanks
Neurocrine Biosciences: Guggenheim raises PT to $175, maintains Buy rating. - AInvest
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $140 to $200 - 富途牛牛
Neurocrine Biosciences Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Neurocrine (NBIX) Q2 Revenue Jumps 17% - Nasdaq
Neurocrine Biosciences’ Earnings Call Highlights Growth - TipRanks
Neurocrine Biosciences: JP Morgan Maintains Neutral, PT Raised to $145. - AInvest
The Analyst Verdict: Neurocrine Biosciences In The Eyes Of 17 Experts - 富途牛牛
Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales - Investing.com Canada
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $141 to $192 - 富途牛牛
Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drug - Endpoints News
Neurocrine Bio. price target raised to $145 from $140 at Mizuho - Investing.com Canada
Neurocrine Biosciences: Wedbush raises PT to $141, maintains Outperform rating. - AInvest
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters (NASDAQ:NBIX) - Seeking Alpha
Should you hold or exit Neurocrine Biosciences Inc. nowExpert Verified Stock Trade Ideas Backed by Data - metal.it
Neurocrine Bio. stock price target raised by BMO Capital to $124 - Investing.com
Neurocrine refines INGREZZA net sales guidance to $2.5B-$2.55B while CRENESSITY surges, driving revenue growth and pipeline expansion - MSN
0.75%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):